A Covid-19 vaccine produced by India’s government research institute Bharat Biotech is expected to work against the extra-contagious strain of the virus first detected in the UK, a new study suggests.

The findings on Covaxin have been published on website bioRxiv, which focuses on research papers not yet certified by peer review. The small-scale study, involving 26 participants, was conducted by the vaccine’s manufacturer itself.

“We successfully isolated and characterized the SARS-CoV-2 from UK returnees in India with all signature mutations of the UK-variant,” the pre-print version of the study reads. (RT)